Data from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Authors:
- Jason J. LukeJLJason J. Luke
- Karen GelmonKaren Gelmon
- Lillian L. SiuLSLillian L. Siu
- Victor MorenoVictor Moreno
- Jayesh DesaiJDJayesh Desai
- Carlos A. Gomez-RocaCGCarlos A. Gomez-Roca
- Matteo S. CarlinoMCMatteo S. Carlino
- Russell K. PachynskiRPRussell K. Pachynski
- Rasha CosmanRCRasha Cosman
- Quincy Siu-Chung ChuQCQuincy Siu-Chung Chu
- Silvia DamianSDSilvia Damian
- Giuseppe CuriglianoGCGiuseppe Curigliano
Open Access
- 3 June 2025
- other
- Published by American Association for Cancer Research (AACR)